ArticleFrontiers in pharmacology2025
Disproportionality evaluation of adverse effects and suicide/self-injury risk factors associated with vortioxetine: a large-scale pharmacovigilance study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Adverse events associated with antidepressants may contribute to stigma, morbidity, and suicidal behaviour among patients. Effectively assessing the risk of potential AEs induced by antidepressants is crucial for guiding treatment strategy selection. In this study, the antidepressant-related AEs of vortioxetine and other antidepressants were analysed using data from the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER), with a particular focus on the risk factors for suicide and selfinjury events. Methods: Demographic data, adverse events types, and frequencies for patients using vortioxetine were summarized from the FDA Adverse Event Reporting System and Japanese Adverse Drug Event Report database, covering the third quarter of 2013 to the third quarter of 2024, through data cleaning, analysis, and statistical methods. The risk signals were identified using four disproportionality methods. Results: There were 13,097 and 509 AE reports listing vortioxetine as the "primary suspect" from the FAERS and JADER, respectively. Twenty-seven system organ classes and 2002 preferred terms (PTs) signals were identified, and vortioxetine JADER with 25 SOCs (218 PTs). Notable differences existed in the signal strength values obtained for identical PTs from the two databases. More than 20 novel AEs, not listed on the product label, were identified. Notably, stronger correlations for suicide/self-injury were observed for vortioxetine via multivariate logistic regression analysis. Additionally, compared with their male counterparts, female patients are significantly more susceptible to suicide/self-injury. The risk of suicide/self-injury was significantly lower in individuals aged ≥25 years than in those aged 0-24 years (p < 0.05), and the lowest risk was found in patients aged ≥60 years (OR 0.26 (0.22-0.30), p < 0.001). Discussion: The detected risk signals indicate only the statistical correlation between the target drug and the target adverse reaction and do not indicate the inevitable causal link between the drug and adverse response. Likely confounders include vortioxetine's preferential prescription in complex patient populations (attributed to its broad-spectrum efficacy and safety profile) rather than intrinsic drug effects. Future studies should consider controlling for these confounders to provide a more definitive assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.